

Cervical cancer screening and the COVID pandemic: the importance of co-testing with Pap and HPV


The COVID-19 pandemic has reduced cervical cancer screening and associated cancer diagnoses—**putting women's lives at risk.**



Cervical cancer is still a concern¹⁻⁴

- Screening visits went down during the pandemic³
- As a consequence, diagnoses are down
- Patients may be under-screened
- As a result, make sure patients ages 30-65 receive the best: **co-testing**

Double-digit decline in cervical cancer diagnoses within 1 year of the start of the COVID-19 pandemic⁴




Co-testing matters

Co-testing with Pap and HPV together helps identify more cases of cancer and precancer than either test alone. In a recent Quest Diagnostics Health Trends[®] retrospective, longitudinal study:⁵

Co-testing versus HPV alone

HPV was not detected in 1 in 5 cases of cervical cancer⁵


Data <12 months to cancer diagnosis



Co-testing versus Pap alone

Pap alone did not identify presence of a pre-cancerous condition in 11% of patients⁵

Data <12 months to precancer diagnosis



Guidelines support co-testing

Guidelines from leading health organizations, ACOG, USPSTF, and ASCCP continue to endorse co-testing as a Grade A level screening option in women ages 30-65.⁶⁻⁸

Review the guidelines at
[QuestWomensHealth.com](https://www.questwomenshealth.com)



Give her the best: give her co-testing

Smart Codes make it easy to incorporate co-testing into your practice

Smart Codes: a solution from Quest to help you order the combination of an image-guided Pap, HPV test, and STI testing appropriate for her age and risk factors.⁶⁻⁸

Learn more at [QuestSmartCodes.com](https://www.questsmartcodes.com)

Quest Advanced® Women's Health



Delivering care throughout a woman's life requires testing that you can rely on. Our commitment to you is to make testing more actionable and accessible for you, your patients, and their families.

To learn more about co-testing, contact your Quest Diagnostics® sales representative or visit [QuestWomensHealth.com](https://www.questwomenshealth.com)

Pap and HPV are screening tests for cervical cancer. They are not diagnostic tests when used as part of routine screening, and are subject to false-negative and false-positive results. These tests are most reliable when a satisfactory sample, regularly obtained, is submitted with relevant clinical findings and history, and when the Pap and HPV results are evaluated along with historic and current clinical information.

References

1. Bakouny Z, Paciotti M, Schmidt AL, et al. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. *JAMA Oncol*. 2021;7(3):458-460. doi:10.1001/jamaoncol.2020.7600
2. Peters B, Pfaff C. The impact of COVID-19 on cervical, breast cancer screenings. *Pharm Times*. 2022;4(3):19-21.
3. Miller MJ, Xu Lanfang, Qin J, et al. Impact of COVID-19 on cervical cancer screening rates among women aged 21-65 years in a large integrated health care system—Southern California, January 1-September 30, 2019, and January 1-September 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(4):109-113. doi:10.15585/mmwr.mm7004a1
4. Kaufman HW, Chen Z, Niles JK, et al. Changes in newly identified cancer among US patients from before COVID-19 through the first full year of the pandemic. *JAMA Netw Open*. 2021;4(8):e2125681. doi:10.1001/jamanetworkopen.2021.25681
5. Kaufman HW, Alagia DP, Chen Z, et al. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the United States. *Am J Clin Pathol*. 2020;154(4):510-516. doi:10.1093/ajcp/aqaa074
6. American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. Practice advisory. Updated April 2021. Accessed July 1, 2022. <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines>
7. US Preventive Services Task Force. Final recommendation statement: cervical cancer: screening. August 21, 2018. Accessed July 1, 2022. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening>
8. ASCCP Screening Guidelines. 2020. Accessed July 1, 2022. <https://www.asccp.org/screening-guidelines>

Image content features models and is intended for illustrative purposes only.

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. SB11924 1/2023